Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Lymphoid 1Breast 1

Conditions

Neoplasms 12Breast Neoplasms 8Carcinoma, Non-Small-Cell Lung 7Lung Neoplasms 5Prostatic Neoplasms 4Solid Tumor 3Neoplasm Metastasis 3Melanoma 3Recurrence 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Gastrointestinal Stromal Tumors 2Colonic Neoplasms 2Choledocholithiasis 2Carcinoma 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Terminal Cancer 1Synovitis, Pigmented Villonodular 1Stomach Neoplasms 1Solid Tumours 1Solid Tumour 1Solid Tumors 1Skin Neoplasms 1Respiratory Aspiration 1Respiration Disorders 1Rectal Neoplasms 1Rare Diseases 1Prostate Cancer Patients 1

Interventions

Cisplatin 30Pemetrexed 21Gemcitabine 11Radiotherapy 6Nivolumab 6Drug Therapy 6Cyclophosphamide 6Carboplatin 6durvalumab 4Vinorelbine 4Chemotherapy, Adjuvant 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3sodium thiosulfate 3sargramostim 3Ipilimumab 3Doxorubicin 3raltitrexed 2pembrolizumab 2cediranib 2SS1(dsFv)PE38 2Radiotherapy, Intensity-Modulated 2Psychiatric Rehabilitation 2Photochemotherapy 2Neoadjuvant Therapy 2Methotrexate 2Interferon-alpha 2Imatinib Mesylate 2Granulocyte-Macrophage Colony-Stimulating Factor 2Gefitinib 2Everolimus 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Mesothelioma, Malignant × Midazolam × Clear all
NCT01655225 2022-04-08

A Study of LY3023414 in Participants With Advanced Cancer

Eli Lilly and Company

Phase 1 Completed
156 enrolled
BreastLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lymphoma, Lymphoma, Non-Hodgkin, Mesothelioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡